Standout Papers
Citation Impact
Citing Papers
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
2006
Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized
2007
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
2006
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
2008
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
2008
Hallmarks of Cancer: The Next Generation
2011 Standout
Identification of the Interaction Site within Acyl-CoA:Cholesterol Acyltransferase 2 for the Isoform-specific Inhibitor Pyripyropene A
2008 StandoutNobel
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
2013
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
2011
Calmodulin is responsible for Ca2+-dependent regulation of TRPA1 Channels
2017
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
2007
Structure of the signal recognition particle interacting with the elongation-arrested ribosome
2004 StandoutNatureNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Human cancers express mutator phenotypes: origin, consequences and targeting
2011
Structure of the TRPA1 ion channel suggests regulatory mechanisms
2015 StandoutNatureNobel
Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung Adenocarcinomas
2007
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
2020 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Using tumour phylogenetics to identify the roots of metastasis in humans
2015
A view on drug resistance in cancer
2019 StandoutNature
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
2010
Comparing antibody and small-molecule therapies for cancer
2006
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
2012
Genetically engineered mouse models of pancreatic adenocarcinoma
2013
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
2007
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
2005
Imaging in the era of molecular oncology
2008 StandoutNature
Fragment Length of Circulating Tumor DNA
2016
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer
2006
Irritant-evoked activation and calcium modulation of the TRPA1 receptor
2020 StandoutNatureNobel
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2007
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
2006
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
2008
Lung Cancer and Chronic Obstructive Pulmonary Disease: Needs and Opportunities for Integrated Research
2009
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
2008
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011 StandoutNatureNobel
Telomere Length and Telomerase Expression in Atypical Adenomatous Hyperplasia and Small Bronchioloalveolar Carcinoma of the Lung
2007
Translocation of proteins across the endoplasmic reticulum
1993
Lung cancer: current therapies and new targeted treatments
2016 Standout
Phosphoinositide Regulation of TRP Channels
2014
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Loss of TGFβ Signaling Destabilizes Homeostasis and Promotes Squamous Cell Carcinomas in Stratified Epithelia
2007
ErbBs in lung cancer
2008
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
2006
Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
2006
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
Epidemiology of Lung Cancer
2013
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
2006
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
2005
γH2AX and cancer
2008
TGFβ in Cancer
2008 Standout
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L
2006
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2005 Standout
Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants
2011
EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer
2006
Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase
2009 StandoutNobel
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
COVID-19: consider cytokine storm syndromes and immunosuppression
2020 Standout
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing
2020
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
2007
Clonal evolution in cancer
2012 StandoutNature
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
The Hallmarks of Aging
2013 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Predicting the outcome of chemotherapy for lung cancer
2006
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Lung cancer in never smokers — a different disease
2007
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
2005
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
2015
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
2007
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
2006
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas
2006
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Targeted and Equally Distributed Delivery of mRNA to Organs with Pentaerythritol-Based One-Component Ionizable Amphiphilic Janus Dendrimers
2023 StandoutNobel
ACAT1 and ACAT2 Membrane Topology Segregates a Serine Residue Essential for Activity to Opposite Sides of the Endoplasmic Reticulum Membrane
2000
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
2007
Syndromes of Telomere Shortening
2009
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
2006
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features
2005
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
2005
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
2006
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
2013
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
2006
Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
2021 StandoutNobel
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
2009
A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer
2006
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells BearingEGFRGene Mutation and Amplification
2007
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
2005
Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I
2018
Works of Lin Li being referenced
Application of a methylation gene panel by quantitative PCR for lung cancers
2006
Direct inhibition of the cold-activated TRPM8 ion channel by Gαq
2012
Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis
2018
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration
2017
Ulcerative Colitis Is a Disease of Accelerated Colon Aging: Evidence From Telomere Attrition and DNA Damage
2008
Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
2007
Clonal expansions in ulcerative colitis identify patients with neoplasia
2009
Transforming Growth Factor β Receptor Type II Inactivation Induces the Malignant Transformation of Intestinal Neoplasms Initiated by Apc Mutation
2006
Membrane topology and biogenesis of eukaryotic signal peptidase.
1993